{"id":47122,"date":"2022-08-10T01:01:40","date_gmt":"2022-08-09T23:01:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\/"},"modified":"2022-08-10T01:01:40","modified_gmt":"2022-08-09T23:01:40","slug":"catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\/","title":{"rendered":"Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity"},"content":{"rendered":"
\n

SOMERSET, N.J.–(BUSINESS WIRE)–Catalent, Inc. (NYSE: CTLT), the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it has reached an agreement to acquire Metrics Contract Services (Metrics), a full-service specialty Contract Development and Manufacturing Organization (CDMO) with a facility in Greenville, North Carolina, for $475 million from Mayne Pharma Group Limited (ASX: MYX) (Mayne Pharma). Upon completion, the acquisition will strengthen Catalent\u2019s capabilities in integrated oral solid formulation development, manufacturing, and packaging to help customers simplify and accelerate their programs, while also expanding Catalent’s capacity to handle highly potent compounds.\n<\/p>\n

<\/a><\/p>\n

\nThe 333,000 square-foot Greenville facility features comprehensive capabilities to accelerate and de-risk customer programs from early development through commercial launch through a streamlined one-site solution. Over the past five years, the facility has seen more than $100 million in capital improvements and now includes 16 manufacturing suites, with 11 designed to handle highly potent compounds, as well as two packaging lines that can support a large variety of development and commercial supply programs. The facility\u2019s estimated annual production capacity exceeds one billion oral solid dose units.\n<\/p>\n

\n\u201cThis acquisition will further expand Catalent\u2019s ability to meet our customers\u2019 expectations in fast-growing areas of the business and patient need. The experienced team and consistently improved, state-of-the-art facility in Greenville will provide Catalent\u2019s customers with immediate, fit-for-scale capacity for in-demand highly potent drugs and other oral solid small-to-mid-size batch needs. This capacity is particularly important for customers with R&D pipelines featuring accelerated, orphan, and rare disease programs for oncology and other important therapeutic areas,\u201d said Dr. Aris Gennadios, Group President of Catalent\u2019s Pharma & Consumer Health segment.\n<\/p>\n

\n\u201cOver the past several years, Metrics has undergone a period of transformational change to expand its footprint and service offering, becoming a global end-to-end novel oral solid CDMO. Catalent, a global leader in advanced drug development and manufacturing, is well-positioned to continue to invest in and accelerate the growth of Metrics and we believe this transaction will be extremely positive for our Greenville team and customers,\u201d said Scott Richards, Chief Executive Officer of Mayne Pharma.\n<\/p>\n

\nThe new facility will seamlessly integrate into Catalent\u2019s industry-leading oral development and manufacturing network, which includes flagship sites for large-scale and controlled release oral solids manufacturing in Winchester, Kentucky; softgel development and manufacturing in St. Petersburg, Florida; and additional facilities with bioavailability enhancement technologies and complex oral solids manufacturing platforms.\n<\/p>\n

\nThe acquisition is expected to close before the end of this calendar year, subject to customary closing conditions, and the entire team of over 400 employees will join Catalent. Mayne Pharma and Catalent have also agreed on the terms of a long-term supply agreement whereby the Greenville facility will continue to manufacture multiple Mayne Pharma products. Catalent will pay the purchase price for this all-cash acquisition using a combination of cash on hand, existing credit facilities, and, depending on market conditions, potentially new debt financing. The closing of the acquisition is not contingent on any financing activity.\n<\/p>\n

\nNotes for Editors<\/span>\n<\/p>\n

\nABOUT CATALENT<\/b>\n<\/p>\n

\nCatalent, Inc. (NYSE: CTLT), an S&P 500\u00ae company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is the industry\u2019s preferred partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of nearly 7,000 products to over 1,000 customers annually. Catalent\u2019s expert workforce of approximately 19,000 includes more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. For more information, visit www.catalent.com<\/a>.\n<\/p>\n

\nABOUT METRICS CONTRACT SERVICES<\/b>\n<\/p>\n

\nMetrics Contract Services, a division of Mayne Pharma Group Limited, is a full-service pharmaceutical development and manufacturing organization serving clients worldwide delivering proven scientific and operational excellence for novel oral dosage forms. Metrics provides formulation development, analytical testing and commercial manufacturing from its single-campus facility in Greenville, North Carolina. For more information, visit www.metricscontractservices.com<\/a>.\n<\/p>\n

\nFORWARD-LOOKING STATEMENTS<\/b>\n<\/p>\n

\nThis release contains both historical and forward-looking statements. All statements other than statements of historical fact, are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the expected consummation of the Metrics acquisition. These forward-looking statements generally can be identified by the use of statements that include phrases such as \u201cbelieve,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cforesee,\u201d \u201clikely,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cwould,\u201d or other words or phrases with similar meanings. Similarly, statements that describe Catalent\u2019s objectives, plans, or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent\u2019s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: the current or future effects of the COVID-19 pandemic or any global health developments on Catalent\u2019s and its customers\u2019 or suppliers\u2019 businesses; participation in a highly competitive market and increased competition that may adversely affect Catalent\u2019s business; demand for its offerings, which depends in part on its customers\u2019 research and development and the clinical and market success of their products; product and other liability risks that could adversely affect Catalent\u2019s results of operations, financial condition, liquidity and cash flows; failure to comply with existing and future regulatory requirements; failure to provide quality offerings to customers could have an adverse effect on Catalent\u2019s business and subject it to regulatory actions and costly litigation; problems providing the highly exacting and complex services or support required; global economic, political and regulatory risks to Catalent\u2019s operations; inability to enhance existing or introduce new technology or service offerings in a timely manner; inadequate patents, copyrights, trademarks and other forms of intellectual property protections; fluctuations in the costs, availability, and suitability of the components of the products Catalent manufactures, including active pharmaceutical ingredients, excipients, purchased components and raw materials; changes in market access or healthcare reimbursement in the United States or internationally; fluctuations in the exchange rates of the U.S. dollar against other currencies; adverse tax legislative or regulatory initiatives or challenges or adjustments to Catalent\u2019s tax positions; loss of key personnel; risks generally associated with information systems; inability to complete any future acquisition, including the pending acquisition of Metrics, or other transaction that may complement or expand its business or divest of non-strategic businesses or assets and difficulties in successfully integrating acquired businesses and realizing anticipated benefits of such acquisitions; risks associated with timely and successfully completing, and correctly anticipating the future demand predicted for, capital expansion projects at existing facilities, offerings and customers\u2019 products that may infringe on the intellectual property rights of third parties; environmental, health and safety laws and regulations, which could increase costs and restrict operations; labor and employment laws and regulations or labor difficulties, which could increase costs or result in operational disruptions; additional cash contributions required to satisfy Catalent\u2019s existing pension plan obligations; substantial leverage that may limit its ability to raise additional capital to fund operations and react to changes in the economy or in the industry; and exposure to interest-rate risk to the extent of its variable-rate debt preventing it from meeting its obligations under its indebtedness. For a more detailed discussion of these and other factors, see the information under the caption \u201cRisk Factors\u201d in Catalent\u2019s Annual Report on Form 10-K for the fiscal year ended June 30, 2021, filed August 30, 2021. All forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent does not undertake to update any forward-looking statement as a result of new information or future events or developments except to the extent required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact:<\/b>
Chris Halling
\n
+44 (0)7580 041073
\n
chris.halling@catalent.com<\/a>\n<\/p>\n

\nInvestor Contact:<\/b>
Paul Surdez
\n
+1 (732) 537-6325
\n
investors@catalent.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SOMERSET, N.J.–(BUSINESS WIRE)–Catalent, Inc. (NYSE: CTLT), the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it has reached an agreement to acquire Metrics Contract Services (Metrics), a full-service specialty Contract Development and Manufacturing Organization (CDMO) with … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47122","6":"format-standard","7":"category-industry"},"yoast_head":"\nCatalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SOMERSET, N.J.–(BUSINESS WIRE)–Catalent, Inc. (NYSE: CTLT), the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it has reached an agreement to acquire Metrics Contract Services (Metrics), a full-service specialty Contract Development and Manufacturing Organization (CDMO) with ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-09T23:01:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220808005742\/en\/772236\/21\/Catalent_CMYK.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity\",\"datePublished\":\"2022-08-09T23:01:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\\\/\"},\"wordCount\":1399,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220808005742\\\/en\\\/772236\\\/21\\\/Catalent_CMYK.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\\\/\",\"name\":\"Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220808005742\\\/en\\\/772236\\\/21\\\/Catalent_CMYK.jpg\",\"datePublished\":\"2022-08-09T23:01:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220808005742\\\/en\\\/772236\\\/21\\\/Catalent_CMYK.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220808005742\\\/en\\\/772236\\\/21\\\/Catalent_CMYK.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\/","og_locale":"en_US","og_type":"article","og_title":"Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity - Pharma Trend","og_description":"SOMERSET, N.J.–(BUSINESS WIRE)–Catalent, Inc. (NYSE: CTLT), the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it has reached an agreement to acquire Metrics Contract Services (Metrics), a full-service specialty Contract Development and Manufacturing Organization (CDMO) with ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-09T23:01:40+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220808005742\/en\/772236\/21\/Catalent_CMYK.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity","datePublished":"2022-08-09T23:01:40+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\/"},"wordCount":1399,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220808005742\/en\/772236\/21\/Catalent_CMYK.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\/","url":"https:\/\/pharma-trend.com\/en\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\/","name":"Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220808005742\/en\/772236\/21\/Catalent_CMYK.jpg","datePublished":"2022-08-09T23:01:40+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220808005742\/en\/772236\/21\/Catalent_CMYK.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220808005742\/en\/772236\/21\/Catalent_CMYK.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/catalent-to-acquire-metrics-contract-services-for-475-million-to-expand-high-potent-capabilities-and-oral-development-and-manufacturing-capacity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47122","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47122"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47122\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47122"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47122"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}